Ascierto and colleagues demonstrated that patients (stage IIC to IIIC) with BRAFV600E/K melanoma and low TILs had a greater benefit in terms of disease-free survival after adjuvant BRAF inhibition (vemurafenib) compared to those with high TILs.52 This evidence concerns the gene BRAF and melanoma.